X0306 4 2013-11-18 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001277495 BOESS CARSTEN 33 HAYDEN AVE LEXINGTON MA 02421 false true false false SVP, Chief Financial Officer Common Stock 2013-11-18 4 M false 9927 1.7 A 9927 D Common Stock 2013-11-18 4 S false 3861 53.98 D 6066 D Common Stock 2013-11-18 4 S false 1765 54.97 D 4301 D Common Stock 2013-11-18 4 S false 3801 55.99 D 500 D Common Stock 2013-11-18 4 S false 500 57.2 D 0 D Stock Option (Right to Buy) 1.7 2013-11-18 4 M false 9927 0 D 2021-05-25 Common Stock 9927 59568 D The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 13, 2013. The Stock Option granted the reporting person an option to purchase 158,840 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 05/16/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $53.45 to $54.39. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $54.55 to $55.33. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $55.62 to $56.45. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $57.14 to $57.37. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. /s/ Christopher J. Heberlig, Attorney-in-Fact 2013-11-20